Roughly 1 percent of Americans suffer from schizophrenia, which is one of the 15 leading causes of disability worldwide, the FDA reports ... or kidney disease. Even so, the drug offers a promising ...
Travere Therapeutics TVTX announced that the FDA granted ... immunosuppressive drug Filspari (sparsentan) in IgA nephropathy (IgAN) indication, a rare progressive kidney disease.
The US FDA has approved a new orphan drug to treat patients with Cushing’s disease who cannot be helped through surgery. Novartis’ Signifor (pasireotide diaspartate) injection has been ...
The FDA has approved Alnylam’s gene silencing drug ... As the kidney function worsens, oxalate can build up and damage other organs including the heart, bones and eyes. The disease is also ...
The FDA has approved Cobenfy, the first new type of schizophrenia drug in decades. Cobenfy doesn’t appear to have the same severe side effects as older antipsychotic medicines — like weight ...
The FDA says people with known liver impairment or moderate to severe kidney impairment should not use the drug. Summer Colling, a senior analyst at Citeline, says the novel muscarinic mechanism ...
director of the Division of Psychiatry at the FDA’s Center for Drug Evaluation and Research. The active ingredients in Cobenfy are xanomeline and trospium chloride. The drug is designed to help ...
Basel, September 17, 2024 – Novartis today announced that the US Food and Drug ... disease-free survival (iDFS) benefit was consistently observed across all patient subgroups 3-6. “The FDA ...
17, 2024 /PRNewswire/ -- Novartis today announced that the US Food and Drug ... "The FDA approval of Kisqali for this early breast cancer population, including those with N0 disease, is a pivotal ...
26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ... system as a possible treatment for Alzheimer’s disease, since manipulating it seemed to reduce ...